Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Requests Addl. Data On Novartis' Menveo For Expanded Use In Infants,toddlers

RELATED NEWS
Trade NVS now with 

Novartis (NVS: Quote) said it has received a Complete Response letter from the US Food and Drug Administration or FDA on its application for the expanded use of Menveo in infants and toddlers from 2 months of age.

Novartis submitted the supplemental Biologics License Application or sBLA for Menveo to the FDA in April 2011. The Complete Response letter indicated that the FDA has completed the current review cycle and requests answers to additional questions prior to proceeding with further review of the sBLA. Novartis would work with the FDA to address these questions.

Meningococcal Oligosaccharide Diphtheria CRM Conjugate Vaccine, Menveo, is already approved for use in individuals 2 to 55 years of age in the U.S.

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Suggesting that the economy is gaining traction, the Conference Board released a report on Thursday showing a bigger than expected increase by its index of leading U.S. economic indicators in July. Results of a survey released by the Federal Reserve Bank of Philadelphia on Thursday showed that regional manufacturing activity unexpectedly grew at an accelerated rate in the month of August, with the index of activity in the sector reaching a three-year high. Existing home sales in U.S. unexpectedly rose to a ten-month high in the month of July, according to a report released by the National Association of Realtors on Thursday. NAR said existing home sales climbed to a seasonally adjusted annual rate of 5.15 million in July from a downwardly revised 5.03 million in June.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.